TY - JOUR
T1 - Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia
AU - Ribera, Josep Maria
AU - Morgades, Mireia
AU - Montesinos, Pau
AU - Martino, Rodrigo
AU - Barba, Pere
AU - Soria, Beatriz
AU - Bermúdez, Arancha
AU - Moreno, María José
AU - González-Campos, José
AU - Vives, Susana
AU - Gil, Cristina
AU - Abella, Eugenia
AU - Guàrdia, Ramon
AU - Martínez-Carballeira, Daniel
AU - Martínez-Sánchez, Pilar
AU - Amigo, María Luz
AU - Mercadal, Santiago
AU - Serrano, Alfons
AU - López-Martínez, Aurelio
AU - Vall-Llovera, Ferran
AU - Sánchez-Sánchez, María José
AU - Peñarrubia, María Jesús
AU - Calbacho, María
AU - Méndez, Jose Angel
AU - Bergua, Juan
AU - Cladera, Antonia
AU - Tormo, Mar
AU - García-Belmonte, Daniel
AU - Feliu, Evarist
AU - Ciudad, Juana
AU - Orfao, Alberto
PY - 2018/7/3
Y1 - 2018/7/3
N2 - © 2017, © 2017 Informa UK Limited, trading as Taylor & Francis Group. Native or pegylated (PEG) asparaginase (ASP) are commonly used in treatment of acute lymphoblastic leukemia (ALL), but have been scarcely compared in the same trial in adult patients. Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL. Ninety-one patients received native ASP and 35 PEG-ASP in induction. No significant differences were observed in complete remission, minimal residual disease levels after induction and after consolidation, disease-free survival, and overall survival. No significant differences in grades 3–4 toxicity were observed in the induction period, although a trend for higher hepatic toxicity was observed in patients receiving PEG-ASP. In this trial the type of ASP did not influence patient response and outcome.
AB - © 2017, © 2017 Informa UK Limited, trading as Taylor & Francis Group. Native or pegylated (PEG) asparaginase (ASP) are commonly used in treatment of acute lymphoblastic leukemia (ALL), but have been scarcely compared in the same trial in adult patients. Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL. Ninety-one patients received native ASP and 35 PEG-ASP in induction. No significant differences were observed in complete remission, minimal residual disease levels after induction and after consolidation, disease-free survival, and overall survival. No significant differences in grades 3–4 toxicity were observed in the induction period, although a trend for higher hepatic toxicity was observed in patients receiving PEG-ASP. In this trial the type of ASP did not influence patient response and outcome.
KW - Adult acute lymphoblastic leukemia
KW - Escherichia coli asparaginase
KW - efficacy
KW - native
KW - pegylated
KW - toxicity
U2 - 10.1080/10428194.2017.1397661
DO - 10.1080/10428194.2017.1397661
M3 - Article
SN - 1042-8194
VL - 59
SP - 1634
EP - 1643
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 7
ER -